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Summary
Acute kidney injury (AKI) is a disease entity of major im-
portance, affecting approximately 6% of all patients on the
intensive care unit. The mortality rate exceeds 60%. AKI is
related to several underlying conditions, including sepsis,
nephrotoxicity or major surgery. Ischaemia reperfusion in-
jury or hypoxic conditions may lead to severe injury of the
kidney and is associated with a steep decline in survival
rates of patients. At present, AKI is diagnosed on the basis
of creatinine levels and urine output. Novel markers and
knowledge of their pathophysiological role is of major im-
portance for targeted therapeutic interventions. Noncoding
RNAs (ncRNAs) have recently been introduced and are
the subject of intensive research initiatives. They are ar-
bitrarily separated into small ncRNAs (≤200 nucleotides)
and long ncRNAs (lncRNAs, ≥200 nucleotides). Whereas
small ncRNAs such as microRNAs have been extensively
studied over the past several years, investigations into the
role of linear lncRNAs and circular RNAs (circRNAs) are
largely lacking. The present review article therefore aims
to elucidate in detail the role of microRNAs, lncRNAs and
circRNAs in animal models as well as patients with is-
chaemic AKI and to describe their use as biomarkers as
well as their potential use as therapeutics.
Keywords: acute kidney injury, long non-coding RNA,
microRNAs, circular RNAs, mortality, renal replacement
therapy
Introduction
Acute kidney injury (AKI) is associated with considerable
morbidity and was identified previously as an independent
risk factor for mortality of patients [1]. Even though sig-
nificant advances have been made over the past several
years regarding best supportive care, AKI on the intensive
care unit is still highly prevalent and associated with a high
mortality [2]. As evidenced by a major multinational, mul-
ticentre study involving more than 30,000 critically-ill pa-
tients with AKI on the intensive care unit, the in-hospital
mortality exceeds 60% [3]. Thirteen percent of survivors
who are subsequently discharged from hospital progress to
end-stage kidney disease and remain on dialysis [3]. Is-
chaemia/reperfusion injury (I/R injury) of the kidney rep-
resents one of the major risk factors for the development
of AKI [4]. A variety of different injurious insults in native
kidneys (e.g., during cardiac surgery) culminate in I/R in-
jury [4]. In addition, it is also an unavoidable phenome-
non in transplanted kidneys owing to the transplantation
procedure itself [5]. Because of its prevalence, it repre-
sents a major socioeconomic health problem [4]. During
ischaemic AKI, a transient drop in blood flow to the kid-
ney is followed by a reperfusion period. Reperfusion itself,
though vital to restoration of kidney function, is associat-
ed with significant additional cellular injury [6]. Among
a multitude of different signalling pathways, non-coding
RNAs may also significantly contribute to the induction
and resolution of renal I/R injury.
RNA transcripts without protein-coding potential represent
more than 90% of the human genome [7, 8]. These non-
coding RNA transcripts (ncRNAs) are arbitrarily separated
into long ncRNAs (lncRNAs, ≥200 nucleotides) and small
ncRNAs (≤200 nucleotides). The biogenesis and function
of small ncRNAs such as microRNAs (miRNAs) has pre-
viously been described in detail [6–8]. In contrast, knowl-
edge of the role and function of lncRNAs is largely lack-
ing. The lncRNA class comprises both linear lncRNAs
(named by default as lncRNAs) and circular RNAs (cir-
cRNAs). Current knowledge of the role of these three cat-
egories of ncRNA molecules (miRNAs, lncRNAs, circR-
NAs) in kidney function and ischaemic AKI is reviewed in
the following paragraphs.
Pathophysiology of renal ischaemia/reperfu-
sion injury
As mentioned in the introduction, during ischaemic AKI a
transient drop in blood flow to the kidney is followed by a
reperfusion period, which is associated with significant ad-
ditional cellular injury [6]. The damage inflicted by tissue
ischaemia is subsequently aggravated by a dramatic surge
in reactive oxygen and nitrogen species during reperfusion
[9, 10]. These induce protein modifications, lipid oxida-
tion and DNA double strand breaks, finally culminating in
endothelial dysfunction, neutrophil adherence to endothe-
lium and transendothelial migration, the release of inflam-
matory mediators, cellular calcium overload and eventual-
ly cell death [9, 10]. In the kidney, blood flow to the outer
medulla is disproportionately reduced compared with the
reduction in total blood flow [9, 10]. Thus, epithelial cell
Correspondence:
Johan Lorenzen, MD, Divi-
sion of Nephrology, Univer-
sity Hospital Zürich,
Raemistrasse 100, CH-8091
Zürich, Johan.Loren-
zen[at]usz.ch
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 1 of 8
injury is mainly detected in the S3 segment of the prox-
imal tubule, located in the outer medulla [9, 10]. Inter-
play of several events contributes to the cellular injury ob-
served in the kidney. The damaged endothelium interacts
with and activates inflammatory cells through enhanced
expression of adhesion molecules (e.g., intracellular adhe-
sion molecule-1 [ICAM-1], selectins) [9, 10]. This inter-
action in turn contributes to obstruction of capillaries and
postcapillary venules, further activation and transmigration
of leucocytes, production of cytokines and inflammation in
tubular epithelial cells [9, 10]. Capillary rarefaction in the
inner stripe of the outer medulla ensues as a result of the
development of chronic hypoxia and is an important con-
tributor to post-AKI tubulointerstitial fibrosis and progres-
sion to chronic kidney disease [9, 10]. Cell polarity and
cytoskeletal arrangement is severely impaired in proximal
tubular epithelial cells during ischaemia [9, 10]. Important
phenotypical changes are loss of the proximal tubule brush
border as well as loss of polarity and derangement of ad-
hesion molecules and other membrane proteins and disrup-
tion of cell-cell interactions at adherent and tight junctions
[9, 10].
MicroRNA biogenesis and function
MicroRNAs (miRNAs) have been extensively studied over
the past 10 years and found to have a major role in is-
chaemic AKI [11]. MiRNAs are small noncoding RNA
transcripts with a length of approximately 22 nucleotides,
which may be perceived as being responsible for fine tun-
ing of protein expression by targeting the 3′-untranslated
region of mRNA transcripts, thereby inducing transcrip-
tional repression or transcript degradation [11]. The first
miRNA, lin-4, was identified in Caenorhabditis elegans
during investigation of genetic loci responsible for tem-
poral control of postembryonic development [12, 13]. The
number of identified mature miRNAs in humans exceeds
2000 (www.mirbase.org; release 21), thereby representing
1% of all human genes [14]. MiRNA biogenesis can be
viewed as a two-step process (see fig. 1). Transcription of
miRNA genes by RNA polymerase II results in primary
miRNA transcripts, which are subsequently processed in
the nucleus by the ribonuclease Drosha into precursor
miRNAs with a length of 70 nucleotides [11]. Thereafter, a
Ran-GTP-dependent nucleo/cytoplasmic cargo transporter
named exportin 5 transports precursor miRNAs into the
cytosol [11]. Here, they are further processed by a second
ribonuclease, called Dicer, into a small, double-stranded
RNA duplex, which is composed of an miRNA guide
strand and its complementary passenger strand (miRNA*)
[11]. In order to exert its function, the miRNA guide strand
(in most cases) is incorporated into the RNA-induced si-
lencing complex (RISC), where, with argonaute and other
proteins, the 3′-untranslated region of mRNAs is targeted,
thereby leading to repression of protein translation or
degradation of mRNA [11]. In most cases, miRNA* is de-
graded, but rarely it can also function as a mature miRNA
[11]. MiRNA function can be modulated by miRNA antag-
onists, so-called antimiRs (chemically engineered oligonu-
cleotides targeting specific miRNAs) and miRNA mimics
[11]. These miRNA modulators may have therapeutic po-
tential in the treatment of patients with kidney disease, in-
cluding AKI [11]. In addition to their intracellular regu-
lation and role in the diagnosis and treatment of various
diseases, they are also secreted into blood and urine and
may therefore serve as biomarkers of disease and response
to therapy [15].
MiRNAs in animal models of ischaemic acute
kidney injury
In 2010, an initial study was published that investigated
the role of miRNAs in AKI by modulation of the miRNA
biogenesis machinery through specific deletion of Dicer in
renal proximal tubular epithelium in mice. It was shown
that after bilateral I/R injury of the kidney, Dicer knockout
mice displayed preserved kidney function and reduced tis-
sue damage compared with littermate controls [16].
MiR-192 was associated with AKI in rats [17]. We pre-
viously showed miR-24 to be enriched in the kidney fol-
lowing I/R injury in mice and humans [18]. MiR-24 was
specifically enriched in renal endothelial and tubular ep-
ithelial cells after I/R induction. Through regulation of
its targets H2A histone family, member X, the sphingo-
Figure 1: Biogenesis and function of microRNAs (see text). RISC = RNA-induced silencing complex
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sine-1-phopshate receptor 1, and haem oxygenase 1,
miR-24 induced apoptosis of these cells. Silencing of
miR-24 in mice following I/R injury resulted in a signif-
icant improvement of survival and kidney function, a re-
duction of apoptosis, improved histological tubular epithe-
lial injury and less infiltration of inflammatory cells.
In unilateral renal I/R injury in mice, nine miRNAs were
shown to be regulated differentially compared with control
animals (miR-21, miR-20a, miR-146a, miR-199a-3p,
miR-214, miR-192, miR-187, miR-805, and miR-194) [10,
19]. This signature was confirmed in immunodeficient re-
combination activating gene-2 (RAG-2) / common γ-chain
double-knockout mice, suggesting that the miRNA expres-
sion is independent of influx of inflammatory cells [10,
19]. MiR-21 expression increased in proliferating tubular
epithelial cells, and silencing of miR-21 promoted apop-
tosis [10, 20]. MiR-127 was demonstrated to be altered
in a rat model of renal I/R injury. Here, miR-127 was
postulated to be transcriptionally activated by hypoxia-in-
ducible factor-1α (HIF-1α) and shown to target kinesin
family member 3B (KIF3B) [10, 21]. Endothelial prog-
enitor cells were shown to secrete miRNA-enriched mi-
crovesicles, which ameliorated murine renal I/R injury [10,
21]. Pro-angiogenic and anti-apoptotic miR-126 and
miR-296 were found to be included in microvesicles. In-
jection of microvesicles derived from endothelial progen-
itor cells into rats subjected to renal I/R injury led to pro-
liferation of tubular cells and a reduction in the number
of apoptotic tubular cells, and decreased the infiltration
of leucocytes [10, 22]. MiR-21 was found to contribute
to renoprotection in a process termed ischaemic precondi-
tioning [10, 23]. MiR-21 was associated with a significant
amelioration, while antimir-21-mediated silencing promot-
ed renal I/R injury [10, 23]. These effects were mediated
by modulation of the miR-21 target programmed cell death
protein 4 (PDCD4). MiR-21 was transcriptionally acti-
vated by HIF-1α [10, 23]. MiR-182-5p and miR-21-3p
were associated with the development of AKI in kidney
transplant patients [24]. In vivo silencing of miR-182-5p
in a model of AKI in rats preserved renal function [25].
MiR-126 has previously been shown to have a beneficial
effect regarding the development of AKI in mice [26].
Haematopoietic overexpression of miR-126 increased neo-
vascularisation, preserved kidney function and increased
numbers of bone marrow-derived endothelial cells. The
numbers of circulating Lin−/Sca-1+/cKit+ haematopoietic
stem and progenitor cells were increased [26].
MiRNAs as biomarkers of acute kidney injury
Expression levels of miR-709, miR-217 and miR-696 have
been shown to be altered in plasma and kidney tissue fol-
lowing bilateral renal I/R injury [27]. MiR-10a was elevat-
ed in plasma 1 hour after renal I/R injury in rats and there-
by outperformed levels of creatinine (6 hours) and urea (12
hours) in detection of renal injury [28]. It was also pre-
viously shown to be altered in rat kidney following deep
hypothermic circulatory arrest [29]. MiR-21 und -320 are
increased in plasma and reduced in urine of rats follow-
ing AKI [30]. The expression of miR-200a increases in the
plasma and kidneys of mice following AKI [31]. We were
able to show that miRNAs, specifically miR-210, detect-
ed in the plasma of critically ill patients with AKI serve
as powerful and independent predictors of mortality in this
patient cohort [32]. Urinary miRs were shown to be specif-
ically decreased during acute T-cell mediated renal allo-
graft rejection and to correlate with kidney function at 1
year after transplantation [33].
Relevant microRNAs in animals and human models of
AKI are summarised in table 1.
Long noncoding RNAs – biogenesis and postu-
lated function
The majority of the human genome is transcribed into
RNA transcripts with little or no protein coding potential.
In fact, more than 98% are so called noncoding RNAs
(ncRNAs), which are arbitrarily separated into long ncR-
NAs (lncRNAs, ≥200 nucleotides) and small ncRNAs
(≤200 nucleotides) [7]. Information regarding the function
of lncRNAs, as opposed to miRNAs, is largely lacking.
However, it is now widely accepted that lncRNAs have
major roles in epigenetic processes and cell function in
the developmental phase, as well as during disease [34].
LncRNAs are novel regulatory RNA species, which may
function as master regulators modifying the expression of
mRNAs and miRNAs, and altering chromatin architec-
ture. LncRNAs may either be nuclear-enriched or primar-
ily found in the cytosol. Nuclear lncRNAs may associate
with the chromatin architecture of genes on the same chro-
mosome (in cis) or on another chromosome (in trans) [34].
Cytoplasmic lncRNAs may function as competing endoge-
nous RNAs and thereby regulate the function of miRNAs
[34]. A functional annotation has not been forwarded yet.
This has led to the categorisation of lncRNAs on the basis
of their location in the genome in relation to protein-cod-
ing genes. LncRNAs may therefore be viewed as: sense,
antisense, bidirectional promoter-associated, intronic, in-
tergenic and enhancer-associated [34]. In view of the lack
of a functional annotation, Howard Chang and co-work-
ers have proposed a mechanistic model regarding the role
of lncRNAs [34, 35]. According to this suggested classi-
fication, lncRNAs are classified as: (1) signal lncRNAs,
which are spatiotemporally transcribed in response to de-
velopmental cues, cellular context or diverse stimuli; (2)
decoy lncRNAs, which impact on transcriptional regula-
tion by titrating away transcription factors and other pro-
teins from chromatin; (3) guide lncRNAs, which sequester
ribonucleoprotein complexes and direct them to chromatin
and other specific targets; and (4) scaffold lncRNAs, which
interact with multiple partners to form a chromatin modi-
fying complex (see fig. 2) [34, 35]. To date, the roles of a
small number of lncRNAs have been characterised in more
detail. The long intergenic RNA (lincRNA) Air has been
shown to regulate imprinting, whereas X-chromosome in-
activation has been shown to be influenced by Xist (X-
inactive specific transcript) [34]. The lncRNA H19 has a
tumour-suppressive effect and is imprinted with maternal
expression [34]
LncRNAs in acute kidney injury
Recently, the hypoxic and inflammatory dysregulation pat-
tern of lncRNAs in cultured human proximal tubular ep-
ithelial cells was investigated [36]. The proximal tubular
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epithelial cells were exposed to hypoxia and treated with a
cytokine cocktail implicated in clinical AKI (interleukin-6
[IL-6], tumour necrosis factor-α [TNF-α], and interferon-
γ). A total number of 667 annotated lncRNAs were found,
but only 14 different lncRNAs overlapped between treat-
ment conditions. Hypoxia-sensitive lncRNAs were located
in the vicinity of protein-coding genes, including those
with roles in the Wnt/β-catenin signalling pathway, ATP
metabolism and vitamin D receptor activation, as well as
cellular differentiation. MIR210HG, linc-ATP13A4-8 and
linc-KIAA1737-2 were amongst the most highly upregu-
lated transcripts. These were detectable in human kidney
tissue as well as microdissected proximal tubules from kid-
ney transplant recipients. Addition of blood samples of
sepsis patients to cultured cells induced expression of all
investigated lncRNAs.
The lncRNA RANTES (regulated on activation, normal T-
cell expressed and secreted) is induced in mice with I/R in-
jury [37]. Kidney dysfunction, renal inflammation and tis-
sue injury in RANTES knockout mice were shown to be
ameliorated following renal I/R injury. Nuclear factor-κB
(NF-κB) was transcriptionally activated RANTES. More-
over, a HIF-1α-regulated lncRNA, termed PRINS (psoria-
sis susceptibility-related RNA gene induced by stress), was
proposed to interact with RANTES under hypoxic con-
ditions. In a mouse model of unilateral ureteral obstruc-
tion, a large number of dysregulated lncRNAs was re-
cently identified by means of RNA sequencing [38]. The
antisense lncRNA Arid2-IR was found to be differential-
ly regulated and associated with progressive renal inflam-
mation in a unilateral ureteral obstruction model involving
Smad3-knockout and wild-type littermate control animals
[39]. Recently, our group analysed the contribution of the
hypoxia-regulated lncRNA metastasis associated lung ade-
nocarcinoma transcript 1 (Malat1) to ischaemic AKI [40].
Malat1 was highly induced in kidney biopsies and plasma
of patients with AKI as well as in a mouse model of renal
I/R injury. In addition, its expression increased in ex vivo
sorted hypoxic endothelial and proximal tubular epithelial
cells, as well as in cultured endothelial and proximal tubu-
lar epithelial cells. HIF-1α functioned as a transcriptional
activator of Malat1. Malat1 silencing impaired the prolifer-
ation rate and reduced the number of ECs in the S-phase of
the cell cycle. In vivo, Malat1 knockout and wild-type mice
did not exhibit differences in the levels of renal injury, cap-
illary rarefaction and fibrosis as well as survival rate and
kidney function. RNA sequencing did not reveal differ-
ences in the expression of small RNAs and mRNAs be-
tween groups. LncRNA activated by transforming growth
factor-β (TGF-β) (lncRNA-ATB) is highly upregulated in
kidney biopsies of patients with acute renal allograft rejec-
tion [41].
LncRNAs as biomarkers of acute kidney in-
jury
Our group previously reported an initial study regarding
the release and biomarker potential of lncRNAs in patients
with AKI. Here, the intronic antisense lncRNA transcript
predicting survival in AKI (TapsAKI, alternative nomen-
clature: MGAT3AS1) was shown to be massively in-
creased in blood and kidney biopsies of patients with AKI
[42]. TapsAKI proved to be an independent and powerful
predictor of 28-day survival [42]. TapsAKI may be re-
leased from endothelial and tubular epithelial cells under
stress conditions, since its expression level was increased
by hypoxia or chemical anoxia (ATP depletion).
Table 1: MicroRNAs, their targets and effects in renal ischaemia/reperfusion injury.
MicroRNA Target Organ/cell type Pathophysiological effects Organism Reference
miR-132, miR-362 and
miR-379
/ Kidney / proximal tubular cell Dicer deletion Mouse [16]
miR-21, miR-20a,
miR-146a,
miR-199a-3p, miR-214,
miR-192, miR-187,
miR-805 and miR-194
/ Kidney Signature of kidney ischaemia/reperfusion
injury
Mouse [10, 19]
miR-127 Kinesin family member 3B Kidney / proximal tubular cell Changes in cell adhesion and cytoskele-
ton structure
Rat [21]
miR-126 and miR-296 / EPC-derived MVs / proximal
tubular cell
Inhibition of capillary rarefaction, glomeru-
losclerosis, and tubulointerstitial fibrosis
Mouse [22]
miR-21 Programmed cell death
protein 4
Kidney / proximal tubular cell Reduction of renal injury Mouse [23]
miR-192 / plasma Biomarker of AKI Rat [17]
miR-24 H2A.X, sphingosine
1-phosphate receptor 1,
haem oxygenase-1
Proximal tubular cell, endothe-
lial cell
Amelioration of AKI Mouse [18]
miR-182-5p / / Improvement of kidney function and mor-
phology after AKI
Rat [25]
miR-126 / Haematopoietic overexpres-
sion of miR-126
increased neovascularisation, preserved
kidney function and increased numbers of
bone marrow-derived endothelial cells
Mouse [26]
miR-709, miR-217 and
miR-696
/ Plasma Biomarker of AKI Mouse [27]
miR-10a / Plasma Biomarker of AKI Rat [28]
miR-21 and miR-320 / Plasma Biomarker of AKI Rat [30]
miR-200a / Plasma Biomarker of AKI Mouse [31]
miR-210 / Plasma Biomarker of AKI Human [32]
miR-210 / Urine Biomarker of acute T cell-mediated rejec-
tion of renal allografts
Human [33]
AKI = acute kidney injury; EPC = endothelial progenitor cells; H2A.X = H2A histone family member X; MV = microvesicles
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We subsequently investigated kidney biopsies and urine
of kidney transplant patients with acute T cell-mediated
renal allograft rejection. Three intergenic lncRNAs were
identified: LNC-MYH13-3:1, RP11-395P13.3-001 and
RP11-354P17.15-001 [43]. RP11-354P17.15-001 predict-
ed acute rejection and loss of kidney function at 1 year
after transplantation. Exposure of cultured tubular epithe-
lial cells to the inflammatory cytokine IL-6, increased the
levels of all lncRNAs, but only RP11-395P13.3-001 and
RP11-354P17.15-001 expression increased in the cell cul-
ture supernatant, indicating that these lncRNAs might be
secreted under inflammatory conditions.
LncRNAs with roles in rodent and human models of AKI
are summarised in table 2.
Circular RNAs – biogenesis and postulated
function
Circular RNAs (circRNAs) are suggested to be part of a
so-called competing endogenous RNA class and may func-
tion as miRNA sponge transcripts. They are ubiquitous-
ly distributed and have diverse functions. CircRNAs are
formed as single-stranded, circular molecules, in which the
3′ and 5′ ends are covalently linked [44–46]. The majority
of circRNAs are generated by a process termed back-splic-
ing. Here, a splice donor is joined with an upstream splice
acceptor [45, 46]. They are ∼100 nucleotides in length
and are highly present in the eukaryotic transcriptome and
abundant in exosomes [47]. “Exonic” circRNAs (formed
from exons) can be differentiated from “intronic” circR-
NAs, which contain a 2′-5′ carbon linkage at the branch
point stemming from introns. It is currently believed that
circRNAs are not translated into protein, since they are
lacking a 5′ cap [48]. A characteristic feature of circRNAs
is the “head-to-tail” splice junction, where exons are or-
ganised in reverse order compared with their chromosomal
localisation. This is a consequence of the backsplicing re-
action.
The RNA binding proteins Muscleblind [45], Quaking [49]
or RNA binding motif protein 20 [50] may contribute to
circRNA biogenesis. On the other hand, the RNA-editing
enzyme adenosine deaminase RNA specific (ADAR1)
blocks circRNAs biogenesis [51].
Platelets, neutrophils, B cells and haematopoietic stem
cells may be important sources of circRNAs [52–54]. In
addition, circRNAs may be actively secreted and detected
in exosomes or small vesicles [55].
Figure 2: Mechanistic classification of lncRNAs as signal lncRNAs, which are spatiotemporally transcribed (a), decoy lncRNAs, which impact
on transcriptional regulation by titrating away transcription factors (b), guide lncRNAs, which sequester ribonucleoprotein complexes and direct
them to chromatin and other specific targets (c) and scaffold lncRNAs, which interact with multiple partners to form a chromatin modifying
complex (d). Kcnq1ot1 = potassium voltage-gated channel subfamily Q member 1 antisense transcript 1; MALAT1 = metastasis-associated
lung adenocarcinoma transcript 1; FENDRR = Fox F1 adjacent non-coding developmental regulatory RNA; PRC1 = polycomb repressive com-
plex 1; PRC2 = polycomb repressive complex 2
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Table 2: LncRNAs, their targets and pathophysiological effects in acute kidney injury.
LncRNA Target Annotation Pathophysiological effects Organism Reference
MIR210HG Unknown Intergenic Induced by hypoxia and cytokine treatment
in cultured proximal tubular epithelial cells
Human [36]
linc-ATP13A4-8 Unknown Intergenic Induced by hypoxia and cytokine treatment
in cultured proximal tubular epithelial cells
Human [36]
linc-KIAA1737-2 Unknown Intergenic Induced by hypoxia and cytokine treatment
in cultured proximal tubular epithelial cells
Human [36]
PRINS HIF-1α Intronic induced in hypoxia, regulated in RANTES
knockout mice
Mouse [37]
Arid2-IR NF-κB, IL-1β Intronic Inflammation and fibrosis Mouse [39]
MALAT1 Unknown Intergenic ischaemia/reperfusion-injury with lack of ef-
fect
Mouse [40]
TapsAKI Unknown Antisense Biomarker (plasma) in acute kidney injury Human [42]
RP11-354P17.15-001 Unknown Intergenic Biomarker (urine) of acute T cell-mediated
rejection of renal allografts
Human [43]
Arid2-IR = AT-rich interactive domain-containing protein 2 intronic region; HIF-1α = ; IL-1β = interleukin-1β; MALAT1 = metastasis associated lung adenocarcinoma transcript
1; NF-κB = nuclear factor-κB; PRINS = psoriasis susceptibility-related RNA gene induced by stress; RANTES = regulated on activation, normal T cell expressed and secreted;
TapsAKI = transcript predicting survival in AKI
Recently, it was shown that circRNAs may function as re-
markably stable biomarkers in human blood as a result
of their resistance to exonucleases through circularisation
[56]. Several studies have highlighted their biomarker po-
tential in patients with atherosclerosis [57], disorders of the
central nervous system [58], degenerative diseases [45],
and cancers [55, 59].
Circular RNAs in ischaemic acute kidney in-
jury
The literature on the role of circRNAs in the kidney and es-
pecially AKI is scarce. An initial study showed that circR-
NAs may be important for renal development [60]. RNA
sequencing confirmed that circRNAs are present and en-
riched in the kidney [61]. Several circRNAs have been
shown to be altered in murine ischaemic AKI [62]. Our
group has recently shown that the novel circRNA
ciRS-126 predicts survival of critically ill patients with
AKI [63]. We performed a global circRNA expression
analysis using RNA isolated from blood of patients with
AKI. This expression analysis yielded a number of dysreg-
ulated circRNAs. Circulating concentrations of three novel
circRNAs, identified with array, were validated by means
of quantitative polymerase chain-reaction tests (qPCR) in
blood of patients with AKI. Circular RNA sponge of
miR-126 (or ciRs-126) was the most altered compared
with controls. CiRs-126 was shown to bioinformatically
sponge miR-126-5p, which was found to be highly sup-
pressed in AKI patients and hypoxic endothelial cells. Cox
regression and Kaplan-Meier curve analysis revealed
ciRs-126 to be an independent predictor of 28-day sur-
vival. Circulating concentrations of circRNAs, and more
specifically ciRs-126, in patients with AKI may act as a
predictor of mortality in this patient cohort.
Conclusions
Pharmacological treatment of patients with AKI is limited.
A targeted and specific therapy in proximal tubular cells of
the S3 segment or endothelial cells of the outer medulla,
which are the primary target cells in ischaemic AKI, to
halt or even reverse the progression of AKI development is
largely lacking. Noncoding RNAs may be therapeutically
used to ameliorate or retard disease progression, as recent-
ly shown by us regarding miR-21 silencing in murine di-
abetic nephropathy [64] and chronic allograft dysfunction
following kidney transplantation [65], as well as miR-24
[66] inhibition regarding murine renal ischaemia reperfu-
sion injury. MicroRNAs are highly conserved between dif-
ferent species and therefore hold huge potential as bio-
markers and therapeutic targets in humans with kidney
disease. LncRNAs are novel regulatory RNA species,
which have been shown to critically impact on various cel-
lular functions and may therefore be an ideal candidate for
therapeutic interventions. In general, lncRNA conservation
between species is low, thereby limiting their applicabili-
ty for therapeutic intervention in humans following initial
validation in animal studies. However, their functional and
structural (secondary structure) homology might be much
higher across species. Another obstacle is the fact that cer-
tain lncRNAs have several transcripts. Thus, the identifi-
cation of specific mechanisms of action is not trivial.
The elucidation of the role of circRNAs is still in its infan-
cy. It is currently unclear, how and to what extent they con-
tribute to kidney disease. Future studies will aim to identify
novel circRNAs with implications in kidney disease. Ulti-
mately, modulation of noncoding RNAs may be a viable
therapeutic option in the treatment of patients with kidney
disease.
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